苯磺酸左氨氯地平片治疗高血压的临床效果评价

Evaluation on the clinical effect of levamlodipine besylate tablets in the treatment of hypertension

目的 探讨在高血压临床治疗中应用苯磺酸左氨氯地平片的效果。方法 选取80例高血压患者,采用随机数字表法分为对照组(n=40)及研究组(n=40)。对照组应用缬沙坦胶囊治疗,研究组应用苯磺酸左氨氯地平片治疗。对比两组疗效,血压[收缩压(SBP)与舒张压(DBP)]水平,血脂[总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]水平,生活质量评分,不良反应发生率。结果 研究组总有效率95.00%高于对照组的77.50%,具有统计学差异(P<0.05)。治疗后,研究组SBP(112.34±8.55)mm Hg(1 mm Hg=0.133 kPa)、DBP(71.35±4.16)mm Hg低于对照组的(129.63±8.85)、(80.64±4.24)mm Hg,具有统计学差异(P<0.05)。治疗后,对照组TC为(5.36±0.98)mmol/L,TG为(2.42±0.25)mmol/L,LDL-C为(4.03±0.86)mmol/L,HDL-C为(1.22±0.66)mmol/L,研究组TC为(4.16±0.86)mmol/L,TG为(2.11±0.16)mmol/L,LDL-C为(2.96±0.65)mmol/L,HDL-C为(1.83±0.52)mmol/L;研究组TC、TG、LDL-C均低于对照组,HDL-C高于对照组,具有统计学差异(P<0.05)。研究组生理功能评分为(87.45±4.12)分,生理职能评分为(85.63±4.05)分,躯体疼痛评分为(87.15±4.25)分,总体健康评分为(88.54±4.18)分,生命活力评分为(84.32±4.63)分,社会功能评分为(85.69±4.09)分,情感职能评分为(85.74±4.29)分,精神健康评分为(86.85±4.74)分,均高于对照组的(72.58±3.34)、(73.85±3.18)、(74.63±3.28)、(75.63±3.82)、(74.23±4.01)、(75.05±3.38)、(75.36±4.12)、(75.58±3.88)分,具有统计学差异(P<0.05)。研究组不良反应发生率为5.00%,低于对照组的22.50%,具有统计学差异(χ^(2)=5.165,P=0.023<0.05)。结论 在高血压患者的临床治疗中采取苯磺酸左氨氯地平片效果显著,可使血脂、血压水平降低,控制血压水平在正常范围之内,并提高患者生活质量。

Objective To explore the effect of levamlodipine besylate tablets in clinical treatment of hypertension.Methods 80 patients with hypertension were selected and divided into a control group(n=40)and a study group(n=40)using random numerical table.The control group received valsartan capsule treatment,and the study group received levamlodipine besylate tablet treatment.Both groups were compared in terms of efficacy,blood pressure[systolic blood pressure(SBP)and diastolic blood pressure(DBP)],blood lipid[total cholesterol(TC),triglycerides(TG),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C)],quality of life scores,and incidence of adverse reactions.Results The total effective rate of 95.00%in the study group was higher than 77.50%in the control group,and there was statistical difference(P<0.05).After treatment,the study group had SBP of(112.34±8.55)mm Hg(1 mm Hg=0.133kPa)and DBP of(71.35±4.16)mm Hg,which were lower than(129.63±8.85)and(80.64±4.24)mm Hg in the control group.There was statistical difference(P<0.05).After treatment,in the control group,TC was(5.36±0.98)mmol/L,TG was(2.42±0.25)mmol/L,LDL-C was(4.03±0.86)mmol/L,and HDL-C was(1.22±0.66)mmol/L;in the study group,TC was(4.16±0.86)mmol/L,TG was(2.11±0.16)mmol/L,LDL-C was(2.96±0.65)mmol/L,and HDL-C was(1.83±0.52)mmol/L.TC,TG and LDL-C in the study group were lower than those in the control group,while HDL-C was higher than that in the control group,and there was statistical difference(P<0.05).In the study group,the physical function score was(87.45±4.12)points,the role-physical score was(85.63±4.05)points,the bodily pain score was(87.15±4.25)points,the overall health score was(88.54±4.18)points,and the vitality score was(84.32±4.63)points,the social function score was(85.69±4.09)points,the role-emotional score was(85.74±4.29)points,and the mental health score was(86.85±4.74)points,which were higher than(72.58±3.34),(73.85±3.18),(74.63±3.28),(75.63±3.82),(74.23±4.01),(75.05±3.38),(75.36±4.12),and(75.58±3.88)points in the control group.There was statistical difference(P<0.05).The incidence of adverse reactions of 5.00%in the study group was significantly lower than 22.50%in the control group(χ^(2)=5.165,P=0.023<0.05).Conclusion Levamlodipine besylate tablets shows significant effect on hypertensive patients,which can reduce the level of blood lipids and blood pressure,control the blood pressure level within the normal range,and improve the quality of life of patients.